BIOTON S.A. (PL:BIO)

:BIO

BIO

BIOTON S.A.

RESEARCH TOOLSreports

Want to see PL:BIO full AI Analyst Report?

BIOTON S.A. (BIO) Price & Analysis

0 Followers

BIO Stock Chart & Stats

zł4.07

Market closed

zł4.07

Day’s Range― - ―

52-Week Rangezł3.65 - zł4.70

Previous CloseN/A

VolumeN/A

Average Volume (3M)33.62K

Market Cap

zł342.60M

Enterprise Valuezł415.05M

Total Cash (Recent Filing)zł2.61M

Total Debt (Recent Filing)zł58.75M

Price to Earnings (P/E)84.6

Beta0.15

Next Earnings

Sep 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.05

Shares Outstanding85,864,200

10 Day Avg. Volume22,695

30 Day Avg. Volume33,619

Financial Highlights & Ratios

PEG Ratio-0.80

Price to Book (P/B)0.56

Price to Sales (P/S)1.17

P/FCF Ratio145.62

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.14

Revenue Forecast (FY)zł266.00M

Bulls Say, Bears Say

Bulls Say

Low LeverageA conservative leverage approach provides BIOTON with financial flexibility and reduces risk, supporting long-term sustainability.

Cash Flow ImprovementImproved cash flow generation enhances BIOTON's ability to reinvest in growth opportunities and maintain financial stability.

Revenue GrowthStrong revenue growth indicates increasing demand for BIOTON's products, enhancing its market position and potential for future expansion.

Bears Say

Low Operating Cash FlowLow operating cash flow relative to net income suggests that BIOTON may struggle to cover its operational expenses, affecting financial health.

Negative Net IncomeNegative net income reflects operational inefficiencies, which can hinder BIOTON's ability to invest in growth and return value to shareholders.

Declining Profit MarginsDecreasing profit margins indicate challenges in cost management and pricing power, potentially impacting long-term profitability.

BIO FAQ

What was BIOTON S.A.’s price range in the past 12 months?

BIOTON S.A. lowest stock price was zł3.65 and its highest was zł4.70 in the past 12 months.

What is BIOTON S.A.’s market cap?

BIOTON S.A.’s market cap is zł342.60M.

When is BIOTON S.A.’s upcoming earnings report date?

BIOTON S.A.’s upcoming earnings report date is Sep 15, 2026 which is in 93 days.

How were BIOTON S.A.’s earnings last quarter?

BIOTON S.A. released its earnings results on May 29, 2026. The company reported -zł0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -zł0.06.

Is BIOTON S.A. overvalued?

According to Wall Street analysts BIOTON S.A.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BIOTON S.A. pay dividends?

BIOTON S.A. does not currently pay dividends.

What is BIOTON S.A.’s EPS estimate?

BIOTON S.A.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BIOTON S.A. have?

BIOTON S.A. has 85,864,200 shares outstanding.

What happened to BIOTON S.A.’s price movement after its last earnings report?

BIOTON S.A. reported an EPS of -zł0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.358%.

Which hedge fund is a major shareholder of BIOTON S.A.?

Currently, no hedge funds are holding shares in PL:BIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BIOTON S.A.

Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.